
CLAIMS:

1. A compound of formula (I),



(I)

wherein

A is selected from the group consisting of:

(a) C_5-C_7-cycloalkylene which is unsubstituted or substituted with one or more, preferably 1, 2 or 3, substituents independently selected from fluoro and C_1-C_4-alkyl;

(b) a 5-7 membered unsaturated heterocyclyl containing one carbon-carbon double bond and one oxygen atom as ring member, wherein said heterocyclyl is unsubstituted or substituted with one or more , preferably 1, 2 or 3, substituents, independently selected from fluoro and C_1-C_4-alkyl, preferably 1, 2 or 3, C_1-C_4-alkyl;

(c) C_6-C_{10} aryl which is unsubstituted or substituted with 1, 2 or 3 R^{A2};

(d) a 5-6 membered heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S as ring members, wherein said heteroaryl ring is unsubstituted or substituted on one or more (e.g., 1, 2 or 3) carbon atoms with R^{A3}, and wherein a nitrogen atom, when present in the heteroaryl ring, is unsubstituted or substituted with a substituent selected from the group consisting of: C_1-C_4-alkyl, $–(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, C_3-C_6-cycloalkyl, hydroxy-C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, $N(R^9)(R^{10})$-C_1-C_4-alkyl, $-SO_2$-C_1-C_4-alkyl, $-SO_2$-C_{3-4}-cycloalkyl, $–(CH_2)_p$-Het^{py}, and $-(CH_2)_p–N(R^9)(R^{10})$;

(e) an 8-10 membered heteroaryl ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an 8-10 membered partially saturated hetero-bicyclic ring containing 1 to 3 heteroatoms or heteroatom groups independently selected from 0-3 nitrogen atoms, 0-2 oxygen atoms, 0-1 sulfur atom and 0-1 $S(=O)_2$ group in the hetero-bicyclic ring, wherein said heteroaryl ring or hetero-bicyclic ring is unsubstituted or substituted on a carbon

atom with 1, 2, 3, 4 or 5 R^{A4}, and wherein the hetero-bicyclic ring is further optionally substituted on a carbon atom by oxo and wherein a nitrogen atom, when present, is unsubstituted or substituted with a substituent which is –(CO)-C_1-C_4-alkyl or C_1-C_4-alkyl, and wherein said C_1-C_4-alkyl is optionally substituted with 1 or 2 substituents independently selected from cyano, hydroxy, oxo, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10}; and

wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, C_1-C_4-alkoxy-hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy, fluoro-C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;

wherein A is attached to the rest of the compound of Formula (I) by a carbon atom on A which is sp^2 hybridized;

wherein


B is selected from the group consisting of B^1 and B^2,


wherein B^1 is C_{6-10} aryl which is unsubstituted or substituted with 1, 2, 3 or 4 R^{Ba};


B^2 is a 6-13 membered heteroaryl which comprises 1, 2 or 3 nitrogen atoms, wherein B^2 is unsubstituted or substituted with 1, 2, 3 or 4 R^{Bb};


C is selected from the group consisting of hydrogen, C_1-C_3 alkyl, C_3-C_5 cycloalkyl, fluoro-C_1-C_3 alkyl, cyano, –CH_2–CN, –CH(CN)-CH_3, –CH_2–OH, –CH(OH)-CH_3 and halo;

L is selected from the group consisting of:



,


,



and



wherein n is 1, 2 or 3,


R_L is selected from hydrogen, methyl, ethyl, $–CH_2–CN$ and $–CH_2–OH$, where

G* represents the point of attachment to G;

G is selected from the group consisting of



,


and


;

wherein

R^2 is selected from hydrogen, C_1-C_3 alkyl, -C(O)-C_1-C_3-alkyl, and fluoro;

R^3 is hydrogen;

R^4 is selected from hydrogen, methyl, $–CH_2F$, $–CH_2-OCH_3$ and $–CH_2-N(CH_3)_2$;

R^5 is selected from hydrogen and methyl;

R^6 is hydrogen;

R^7 is selected from hydrogen and methyl;

wherein R^{A2} is independently selected from the group consisting of: NR^9R^{10}, cyano, -$(CH_2)_p$-CN, halo, OH, hydroxy-C_1-C_4-alkyl, –(COOH), –$(CH_2)_p$-COOH, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl-oxy, N(R^9)(R^{10})-C_1-C_4-alkoxy, C_1-C_4-alkyl-carbonyl-oxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy-C_1-C_4-alkyl, -SO_2-C_1-C_4-alkyl, -SO_2-C_{3-4}-cycloalkyl, –$(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, Het^{py}, -$(CH_2)_p$-Het^{py}, –C(=O)-NR^9R^{10}, -$(CH_2)_p$-C(=O)NR^9R^{10};

wherein R^{A3} is independently selected from the group consisting of oxo, NR^9R^{10}, cyano, -$(CH_2)_p$-CN, halo, OH, hydroxy-C_1-C_4-alkyl, –(COOH), –$(CH_2)_p$-COOH, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl-oxy, N(R^9)(R^{10})-C_1-C_4-alkoxy, C_1-C_4-alkyl-carbonyl-oxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy-C_1-C_4-alkyl, -SO_2-C_1-C_4-alkyl, -SO_2-C_{3-4}-cycloalkyl, –$(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, Het^{py}, -$(CH_2)_p$-Het^{py}, –C(=O)-NR^9R^{10}, -$(CH_2)_p$-C(=O)NR^9R^{10}, $(CH_2)_p$–NR^9R^{10};

wherein R^{A4} is independently selected from the group consisting of cyano, CO_2H, halo, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, hydroxy, hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, NR^9R^{10}, (N(R^9)(R^{10})-C_1-C_4-alkyl, (N(R^9)(R^{10})-C_1-C_4-alkyl-oxy, –(CO)-C_1-C_4-alkyl, and R^9R^{10}N-C_1-C_4-alkyl-oxy–(CO)-C_1-C_4-alkyl;

wherein

p is 1 or 2 or 3;

R^9 is selected from hydrogen and C_1-C_4-alkyl;

R^{10} is selected from the group consisting of hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl;

Het^{py} is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring comprising one or two heteroatoms independently selected from O, N and S, or comprising an S-oxide (SO) or S-dioxide (SO_2) group, and wherein said heterocyclic ring is optionally substituted with oxo on one carbon atom, and wherein said heterocyclic ring is optionally further substituted on one or more carbon atoms with 1, 2 or 3 substituents independently selected from C_1-C_4-alkoxy, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, and fluoro-C_1-C_4-alkyl, and wherein the nitrogen atom, if present in said heterocycle, is optionally further substituted with R^{10};


or Het^{py} is a 5- or 6- membered heteroaryl ring, comprising 1, 2 or 3 nitrogen atoms and wherein said heteroaryl ring is optionally substituted with one or more (e.g., 1, 2 or 3) substituents independently selected from NR^9R^{10}, –C(=O)-NR^9R^{10}, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, cyano, OH, and C_1-C_4-alkoxy;

each R^{Ba} is independently selected from the group consisting of hydroxy, NH_2, C_1-C_4-alkyl and halo;

each R^{Bb} is independently selected from the group consisting of C_1-C_4-alkyl, cyclopropyl, fluoro-C_1-C_3-alkyl, cyano, halo, NH_2 and C_1-C_3-alkoxy,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

2. A compound according to claim 1~~,~~ wherein ~~A~~G is ~~selected from the group consisting of~~



~~(a) C_5-C_7-cycloalkylene which is unsubstituted or substituted with one or more, preferably 1, 2 or 3, substituents independently selected from fluoro and C_1-C_4-alkyl;~~

~~(b) 5-7 membered unsaturated heterocyclyl containing one carbon-carbon double bond and one oxygen atom as ring member, wherein said heterocyclyl is unsubstituted or substituted with one or more , preferably 1, 2 or 3, substituents, independently selected from fluoro and C_1-C_4-alkyl, preferably 1, 2 or 3, C_1-C_4-alkyl;~~

~~(c) C_6-C_{10} aryl which is unsubstituted or substituted with 1, 2 or 3 R^{A2};~~

~~(d) 5-6 membered heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S as ring members, wherein said heteroaryl ring is unsubstituted or substituted on one or more (e.g., 1, 2 or 3) carbon atoms with R^{A3}, and wherein a nitrogen atom, when present in the heteroaryl ring, is unsubstituted or substituted with a substituent selected from the group consisting of: C_1-C_4-alkyl, –$(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, C_3-C_6-cycloalkyl, hydroxy-C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, $N(R^9)(R^{10})$-C_1-C_4-alkyl, -SO_2-C_1-C_4-alkyl, -SO_2-C_{3-4}-cycloalkyl, –$(CH_2)_p$-Het^{py}, and -$(CH_2)_p$–$N(R^9)(R^{10})$;~~

~~(e) 8-10 membered heteroaryl ring containing 1, 2 or 3 nitrogen atoms, wherein each nitrogen atom is unsubstituted or substituted with a substituent which is –(CO)-C_1-C_4-alkyl or C_1-C_4-alkyl,~~

and wherein said C_1-C_4-alkyl is optionally substituted with 1 or 2 substituents independently selected from cyano, hydroxy, oxo, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10}, wherein said heteroaryl ring is unsubstituted or substituted on a carbon atom with 1, 2, 3, 4 or 5 R^{A4};

wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, C_1-C_4-alkoxy-hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy, fluoro-C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy; and


(f) 8-10 membered partially saturated hetero-bicyclic ring containing 1-3 nitrogen atoms, or 1-2 oxygen atoms, or 1 sulfur atom or 1 $S(=O)_2$ group in the hetero-bicyclic ring, wherein said hetero-bicyclic ring is unsubstituted or substituted on a carbon atom with 1, 2, 3, 4 or 5 R^{A4}, and wherein the hetero-bicyclic ring is further optionally substituted on a carbon atom by oxo and wherein a nitrogen atom, when present, is unsubstituted or substituted with a substituent which is –(CO)-C_1-C_4-alkyl or C_1-C_4-alkyl, and wherein said C_1-C_4-alkyl is optionally substituted with 1 or 2 substituents independently selected from cyano, hydroxy, oxo, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10}; and

wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, C_1-C_4-alkoxy-hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy, fluoro-C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

3. A compound according to claim 1 or 2, wherein

~~Het^b~~L is ~~a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, C_1-C_4-alkoxy-hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl wherein said C_1-C_4-alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;~~



~~±~~

~~B~~

and R_L is selected from ~~the group consisting of B^1 and B^2;~~

~~B^1 is C_{6-10} aryl which is unsubstituted or substituted with 1, 2, 3 or 4 R^{Ba} and each R^{Ba} is independently selected from the group consisting of hydroxy, C_1-C_4-alkyl and halo;~~

~~B^2 is a 6-10 membered heteroaryl which comprises 1, 2 or 3 nitrogen atoms, wherein B^2 is unsubstituted or substituted with 1, 2, 3 or 4 R^{Bb};~~

~~each R^{Bb} is independently selected from the group consisting of C_1-C_4-alkyl (preferably~~hydrogen, methyl~~), fluoro-C_1-C_3-alkyl, cyano, halo, NH_2 and C_1-C_3-alkoxy,~~

~~Het^{py} is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring comprising one or two heteroatoms independently selected from O, N and S, or comprising an S-oxide (SO) or S-dioxide (SO_2) group, and wherein said heterocyclic ring is optionally substituted with oxo on one carbon atom, and wherein said heterocyclic ring is further substituted on one or more carbon atoms with 1, 2 or 3 substituents independently selected from C_1-C_4-alkoxy, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, and fluoro-C_1-C_4-alkyl, and wherein the nitrogen atom, if present in said heterocycle, is optionally further substituted with R^{10};~~

~~or Het^{py} is a 5- or 6- membered heteroaryl ring, comprising 1, 2 or 3 nitrogen atoms and wherein said heteroaryl ring is optionally substituted with one or more (e.g., 1, 2 or 3) substituents independently selected from NR^9R^{10}, halo, C_1-C_4-alkyl, cyano,~~ , ethyl, –CH_2–CN and –CH_2–OH, ~~and C_1-C_4-alkoxy;~~

~~wherein R^{A4} is independently selected from the group consisting of cyano, CO_2H, halo, C_1-C_4-alkyl, fluoro- C_1-C_4-alkyl, hydroxy, hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, - NR^9R^{10}, $R^9R^{10}N$-C_1-C_4-alkyl-oxy, –(CO)-C_1-C_4-alkyl;~~

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

4.- A compound according to any one of ~~the preceding claims wherein~~

~~Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, C_1-C_4-alkoxy-hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl wherein said C_1-C_4-alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;~~

~~B^2 is a 6-10 membered heteroaryl which comprises 1, 2 or 3 nitrogen atoms, wherein B^2 is unsubstituted or substituted with 1, 2, 3 or 4 R^{Bb};~~


~~Het^{py} is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring comprising one or two heteroatoms independently selected from O, N and S, or comprising an S-oxide (SO) or S-dioxide (SO_2) group, and wherein said heterocyclic ring is optionally substituted with oxo on one carbon atom, and wherein said heterocyclic ring is further substituted on one or more carbon atoms with 1, 2 or 3 substituents independently selected from C_1-C_4-alkoxy, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, and fluoro-C_1-C_4-alkyl, and wherein the nitrogen atom, if present in said heterocycle, is optionally further substituted with R^{10};~~

~~or Het^{py} is a 5- or 6- membered heteroaryl ring, comprising 1, 2 or 3 nitrogen atoms and wherein said heteroaryl ring is optionally substituted with one or more (e.g., 1, 2 or 3) substituents independently selected from NR^9R^{10}, halo, C_1-C_4-alkyl, cyano, OH, and C_1-C_4-alkoxy;~~

~~R^{A4} is independently selected from the group consisting of cyano, CO_2H, halo, C_1-C_4-alkyl, fluoro- C_1-C_4-alkyl, hydroxy, hydroxy-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, $-NR^9R^{10}$ and $R^9R^{10}N$-C_1-C_4-alkyl-oxy,~~

~~or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~


~~5. A compound according to any one of the preceding claims wherein G is~~



~~,~~

~~or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~6. A compound according to any one of the preceding claims, wherein L is~~




~~,~~

~~or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~


~~7. A compound according to claim 6, wherein R_L is hydrogen, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~8. A compound according to any one of~~ the preceding claims, wherein C is selected from C_1-C_3 alkyl, fluoro-C_1-C_3 alkyl, CH_2–CN, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~9~~



or




,

5. A compound according to any one of the preceding claims, wherein B is

~~wherein B is unsubstituted or substituted with 1, 2 or 3 halo, or methyl groups or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~10. A compound according to any one of the preceding claims, wherein B is~~



,

,

where X is N or C-R^{B5};

where R^{B1} is independently selected from hydrogen and C_1-C_4-alkyl;

R^{B2} is independently selected from hydrogen, halo, C_1-C_4-alkyl, cyclopropyl and NH_2;

R^{B3} is independently selected from hydrogen, halo, cyclopropyl and C_1-C_4-alkyl;

R^{B4} is independently selected from hydrogen, halo and C_1-C_4-alkyl, or R^{B3} and R^{B4} together with the atoms to which they are attached, form a 4-6 membered ring fused to the aromatic ring containing X;

R^{B5} is independently selected from hydrogen, halo and C_1-C_4-alkyl,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~11~~6. A compound according to claim ~~10~~5, wherein R^{B2} is independently selected from the group consisting of hydrogen, NH_2, and CH_3, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~12. A compound according to claim 10 or 11~~7. A compound according to claim 5 or 6, wherein R^{B4} is independently selected from hydrogen, halo and C_1-C_4-alkyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

8. A compound according to any one of ~~13. A compound according to any one of~~ claims ~~10~~5 to ~~12~~7, wherein R^{B1} is independently selected from hydrogen and methyl, or a stereoisomer

thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~14.~~ 9. A compound according to any one of claims ~~10~~5 to ~~13, wherein R^{B1} is hydrogen, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~15. A compound according to any one of claims 10 to 14, wherein R^{B3} and R^{B4} are each independently selected from halo and C_1-C_4-alkyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~16. A compound according to any one of claims 10 to 15, wherein R^{B3} is halo and R^{B4} is C_1-C_4-alkyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~


~~17. A compound according to any one of claims 10 to 16, wherein R^{B3} is chloro and R^{B4} is methyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

8~~18. A compound according to any one of claims 10 to 16, wherein R^{B3} is chloro and R^{B4} is chloro, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~19. A compound according to any one of claims 10 to 18~~, wherein X is CH or N, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~20. A compound according to any one of claims 10 to 19, wherein X is CH, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~21.~~10. A compound of formula (Ia)




,

(Ia)

wherein A, B and C are as defined in any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~22~~11. A compound of formula (I) or of formula (Ia~~)~~), according to any one of ~~the preceding~~ claims 1 to 10, wherein A is ~~C_5-C_7 cycloalkylene which is unsubstituted or substituted with one or more, preferably 1, 2 or 3, substituents independently selected from fluoro and C_1-C_4-alkyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~23. A compound of formula (I) or of formula (Ia) according to any one of the preceding claims, wherein A is~~  ~~, where W is O or $C(R^w)_2$, each R^w is independently selected from hydrogen and fluorine, R^c is hydrogen or C_1-C_4-alkyl and A is optionally further substituted with 1, 2 or 3 substituents independently selected from fluoro and C_1-C_4-alkyl, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

~~24. A compound of formula (I) or of formula (Ia) according to any one of claims 1 to 21, wherein A is phenyl which is unsubstituted or substituted with 1, 2 or 3 R^{A2} or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a~~

pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

25. A compound of formula (I) or of formula (Ia) according to any one of claims 1 to 21, wherein A is a 5-6 membered heteroaryl ring containing 1, 2 or 3 heteroatoms independently selected from N, O and S as ring members, wherein said heteroaryl ring is unsubstituted or substituted on one or more (e.g., 1, 2 or 3) carbon atoms with R^{A3}, and wherein a nitrogen atom, when present in the heteroaryl ring, is unsubstituted or substituted with a substituent selected from the group consisting of: C_1-C_4-alkyl, -$(CH_2)_{1-2}$-C_{3-4}-cycloalkyl, hydroxy-C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, N(R^9)(R^{10})-C_1-C_4-alkyl, -SO_2-C_1-C_4-alkyl, -SO_2-C_{3-4}-cycloalkyl, -$(CH_2)_p$-Het^{py}, and -$(CH_2)_p$-N(R^9)(R^{10}), or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

26. A compound of formula (I) or of formula (Ia) according to any one of claims 1 to 21, wherein A is pyridin-1-yl, pyridin-2-yl or pyridin-3-yl, which is unsubstituted or substituted with 1, 2 or 3 substituents independently selected fromNH_2, cyano, halo, OH, hydroxy-C_1-C_4-alkyl, –COOH, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy, di-C_1-C_4-alkylamino-C_1-C_4-alkyl-oxy, C_1-C_4-alkyl-carbonyl-oxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy-C_1-C_4-alkyl, –C(=O)-NR^9R^{10}, NR^9R^{10}, Het^{py} and –$(CH_2)_p$-Het^{py},

wherein

p is 1 or 2;

R^9 is selected from hydrogen and C_1-C_4-alkyl,

R^{10} is selected from hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl,

Het^{py} is NR^{9a}-R^{10a};


R^{9a} and R^{10a} together with the nitrogen form a 4- or 5- or 6- membered saturated or unsaturated heterocyclic ring comprising one or two heteroatoms independently selected from O, N (pyrrolidin-1-yl, azetidin-1-yl, morpholin-1-yl) and S, or an N-oxide thereof, or an S-oxide (SO) or S-dioxide thereof, and wherein said heterocyclic ring is optionally substituted with oxo on one carbon atom on said heterocyclic ring, and wherein said heterocyclic ring is further substituted

with by 1, 2 or 3 substituents independently selected from C_1-C_4-alkoxy, halo, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl and fluoro-C_1-C_4-alkyl;

or R^{9a} and R^{10a} together with the nitrogen form a 4- or 5- or 6- membered heteroaryl ring, comprising 1, 2 or 3 nitrogen atoms and wherein said heteroaryl ring is optionally substituted with one amino group,

a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of an stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

27. A compound of formula (I) or (Ia) according to any one of claims 1 to 21, wherein A is pyridinyl substituted with 1, 2 or 3 substituents independently selected from NH_2, cyano, halo, C_1-C_4-alkyl, fluoro-C_1-C_4-alkyl, C_1-C_4-alkoxy, di-C_1-C_4-alkylamino-C_1-C_4-alkyl-oxy, –C(=O)-NR^9R^{10}, NR^9R^{10},



where p is 0, 1 or 2,;


R^{22} is hydrogen or C_1-C_4-alkyl, or amino;

R^9 is selected from hydrogen and C_1-C_4-alkyl,

R^{10} is selected from hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

28. A compound of formula (I) or of formula (Ia) according to any one of claims 1 to 21, wherein A is




where R^{23} is hydrogen, C_3-C_6-cycloalkyl, C_1-C_4-alkyl, wherein A is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from F, CH_3, CH_2F, CHF_2 and CF_3;

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

29. A compound of formula (I) or of formula (Ia) according to any one of claims 1 to 21, wherein A is pyrimidin-5-yl which is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from C_1-C_4-alkoxy and CH_3, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

30. A compound of formula (I) or of formula (Ia) according to any one of claims 1 to 21, wherein A is selected from the group consisting of












wherein R^{24} is hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl, $-NR^9R^{10}$, C_1-C_4-alkyl, $-SO_2$-C_1-C_4-alkyl, $-SO_2$-C_{3-4}-cycloalkyl or $-(CH_2)_{1-2}$-C_{3-4}-cycloalkyl;





each of R^{4a}, R^{4b}, R^{4c} and R^{4d} is independently selected from hydrogen and C_1-C_4-alkyl,













or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.


~~31. A compound of formula (I) or of formula (Ia) according to any one of the preceding claims 1 to 21, wherein A is selected from the group consisting of:~~


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



and

wherein

y is 0,1 or 2;

x is 0, 1 or 2;

z is 0, 1 or 2;

R^{O} is selected from the group consisting of hydrogen, $NR^{9}R^{10}$, $R^{9}R^{10}N$-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy and C_1-C_4-alkyl;

R^{M} is hydrogen, halo or C_1-C_4-alkyl, wherein said alkyl is optionally substituted by OH, C_1-C_4-alkoxy or $NR^{9}R^{10}$;

R^{N} is hydrogen or C_1-C_4-alkyl, or halo or fluoro-C_1-C_4-alkyl;

R^{q} is independently selected from the group consisting of C_1-C_4-alkyl, hydroxy, C_1-C_4-alkoxy and $NR^{9}R^{10}$;

R^p is C_1-C_4-alkyl;

each R^{p1} is independently selected from hydrogen and C_1-C_4-alkyl;

R^v is independently selected from halogen, C_1-C_4-alkyl and fluoro-C_1-C_4-alkyl;

R^{ae} is selected from the group consisting of hydrogen and C_1-C_4-alkyl, wherein said alkyl is optionally substituted with 1 or 2 substituents selected from cyano, hydroxy, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10};

R^{Ae} is selected from the group consisting of hydrogen, -(CO)-C_1-C_4-alkyl and C_1-C_4-alkyl wherein the C_1-C_4alkyl in each instance is optionally substituted with 1 or 2 substituents selected from cyano, hydroxy, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10};

wherein


R^9 is selected from hydrogen and C_1-C_4-alkyl;


R^{10} is selected from hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl;


wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is optionally further substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;


or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of an stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.


32. A compound of formula (I) or of formula (Ia), according to any one of claims 1 to 21, wherein A is selected from the group consisting of:



,



,



,



,



,



,



,



,



and



,



,



,



,



,



,



,


,


,


,


and


,

wherein z is 0, 1 or 2;

R^v is independently selected from halogen, C_1-C_4-alkyl and fluoro-C_1-C_4-alkyl;

R is hydrogen or C_1-C_4-alkyl, or halo or fluoro-C_1-C_4-alkyl;

R^O is selected from the group consisting of hydrogen, NR^9R^{10}, $N(R^9)(R^{10})$-C_1-C_4-alkyl-oxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, hydroxy-C_1-C_4-alkyl-oxy and C_1-C_4-alkyl;

R^{ae} is selected from the group consisting of hydrogen and C_1-C_4-alkyl, wherein said alkyl is optionally substituted with 1 or 2 substituents selected from cyano, hydroxy, fluoro, C_1-C_4-alkoxy, C_1-C_4-alkoxy-C_1-C_4-alkyl-oxy, Het^b and NR^9R^{10};




R^9 is selected from hydrogen and C_1-C_4-alkyl;

R^{10} is selected from hydrogen, C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy-C_1-C_4-alkyl and di-C_1-C_4-alkyl-amino-C_1-C_4-alkyl;

wherein Het^b is a 4- or 5- or 6- membered heterocyclic ring comprising 1 or 2 heteroatoms or groups independently selected from N, O, S, SO and SO_2, wherein said heterocyclic ring Het^b is unsubstituted or substituted on a carbon atom with one or two substituents independently selected from C_1-C_4-alkyl, hydroxy, cyano, fluoro, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy and fluoro-C_1-C_4-alkyl, and wherein said heterocyclic ring Het^b is further optionally substituted on a carbon atom by oxo, and wherein the nitrogen atom when present in Het^b is further optionally substituted with C_1-C_4-alkyl which is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxy and C_1-C_4-alkoxy;

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~33~~12. A compound of formula (I) or of formula (Ia), according to any one of the preceding claims ~~1 to 21, or claim 31 or claim 32~~, wherein A is selected from the group consisting of:


,

,

,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

~~34~~13. A compound of formula (I) or of formula (Ia) according to claim ~~33~~12, wherein

R^N is hydrogen or C_1-C_4-alkyl;

R^O is hydrogen or NR^9R^{10};

R^v is independently selected from fluoro, chloro and C_1-C_4-alkyl ~~(e.g., methyl);~~;

z is 0 or 1;

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

14. ~~35. A compound of formula (I) or of formula (Ia) according to any one of claims31 to 34, wherein R^{ae} is selected from the group consisting of hydrogen, C_1-C_4-alkyl, -$(CH_2)_2$-Het^b, -CH_2-CN, -$(CH_2)_2$-OH, -$(CH_2)_2$-O-C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, -$(CH_2)_2$-O-$(CH_2)_2$-O-C_1-C_4-alkyl and -$(CH_2)_2$-diC_1-C_4-alkylamino, or wherein R^{Ae} is selected from the group consisting of hydrogen, fluoro-C_1-C_4-alkyl and C_1-C_4-alkyl;~~

~~Het^b is a 4-, 5- or 6- membered heterocyclic ring comprising 1 nitrogen atom and 1 oxygen atom, or 1-2 nitrogen atoms, wherein said heterocyclic ring is unsubstituted or substituted on a carbon atom by one or two substituents independently selected from C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_4-alkoxy and fluoro, and wherein the nitrogen atom when present in the heterocycle is optionally further substituted with C_1-C_4-alkyl,~~

~~or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.~~

36. A compound of formula (I) or of formula (Ia) according to any one of claims 31 to 35, wherein R^{ae} is selected from the group consisting of hydrogen, methyl, $-CH_2-CN$, $-(CH_2)_2-OH$, $-(CH_2)_2-OCH_3$, $-(CH_2)-C(CH_3)_2-OH$, $-(CH_2)_2-O-(CH_2)_2-OCH_3$, $-(CH_2)_2-N(CH_3)_2$ and $-(CH_2)_2-Het^b$;


wherein said Het^b is a 4-, 5- or 6- membered heterocyclic ring comprising 1 nitrogen atom and 1 oxygen atom, or 1-2 nitrogen atoms, wherein said heterocyclic ring is unsubstituted or substituted on a carbon atom by one or two substituents independently selected from C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl C_1-C_4-alkoxy and fluoro, and wherein the nitrogen atom when present in the heterocycle is optionally further substituted with C_1-C_4-alkyl,

or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

37. A compound of formula (I) or of formula (Ia) according to any one of claims 31 to 36, wherein R^{ae} is selected from the group consisting of hydrogen, methyl, $-CH_2-CN$, $-(CH_2)_2-OH$, $-(CH_2)_2-OCH_3$, $-(CH_2)-C(CH_3)_2-OH$, $-(CH_2)_2-O-(CH_2)_2-OCH_3$, $-(CH_2)_2-N(CH_3)_2$, and $-(CH_2)_2-Het^b$, wherein Het^b is selected from the group consisting of azetidin-1-yl, pyrrolidin-1-yl, pyrrolidin-3-yl and morpholin-1-yl, and wherein said heterocyclic ring is optionally further substituted with one or two substituents independently selected from methyl, hydroxy-methyl, methoxy and fluoro, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

38. A compound of formula (I) or of formula (Ia) according to any one of claims 31 to 36, wherein R^{ae} is selected from the group consisting of hydrogen, fluoro-C_1-C_4-alkyl,C_1-C_4-alkyl, $-(CH_2)_2-Het^b$, $-(CH_2)_2-OH$, $-(CH_2)_2-O-C_1-C_4$-alkyl, hydroxy-C_1-C_4-alkyl, $-(CH_2)_2-O-(CH_2)_2-O-C_1-C_4$-alkyl and $-(CH_2)_2-diC_1-C_4$-alkylamino, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.


39. A compound of formula (Ib*),



(Ib*),

wherein A, C, R^{B2}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, wherein A is unsubstituted or substituted as defined in any one of the preceding claims, or a pharmaceutically acceptable salt thereof.


40<u>15</u>. A compound ~~of formula (Ic*),~~



~~(Ic*),~~

~~wherein C, R^{A2}, R^{B2}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, wherein a is 0, 1, 2 or 3, or a pharmaceutically acceptable salt thereof.~~

~~41. A compound of formula (Id*),~~



(Id*),

wherein C, R^{B2}, R^{N}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, wherein the --- lines indicate a single bond or a double bond;

and R^{ae} is as defined above.

42. A compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof, selected from the compound of any one of Examples.

43. A compound which is selected from:

a(*R*)-1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

a(*R*)(*S*)-1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-3-(1-(2-(3-fluoropyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

a(*R*)1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

a(*R*)1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-3-(2-(2-methoxyethyl)-2H-indazol-5-yl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

~~a(*R*)1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-3-(2-(2-hydroxy-2-methylpropyl)-2H-indazol-5-yl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,~~

~~a(*R*)1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-3-(2-(2-(2-methoxyethoxy)ethyl)-2H-indazol-5-yl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,~~

~~a(*R*)1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-3-(4-(hydroxymethyl)phenyl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,~~

~~a(*R*)1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-3-(2-fluoro-4-(2-methoxyethoxy)phenyl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,~~

~~a(*R*)1-(6-(4-(3-amino-5-chloro-6-methyl-1H-indazol-4-yl)-3-(2-(2-methoxyethyl)-2H-indazol-5-yl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,~~

~~a(*R*)1-(6-(4-(3-amino-5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-phenyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,~~

~~or a pharmaceutically acceptable salt thereof.~~

44. ~~A compound~~ which is selected from:

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-5-methyl-3-(1-methyl-1*H*-indazol-5-yl)-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-(1-{2-[(3*S*)-3-fluoropyrrolidin-1-yl]ethyl}-1*H*-indazol-5-yl)-5-methyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-(2-methoxyethyl)-2*H*-indazol-5-yl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-(2-hydroxy-2-methylpropyl)-2*H*-indazol-5-yl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-{6-[(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-{2-[2-(2-methoxyethoxy)ethyl]-2*H*-indazol-5-yl}-5-methyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[4-(hydroxymethyl)phenyl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-(6-{(4*M*)-4-(5-Chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-fluoro-4-(2-methoxyethoxy)phenyl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,


1-(6-{(4*M*)-4-(3-Amino-5-chloro-6-methyl-1*H*-indazol-4-yl)-3-[2-(2-methoxyethyl)-2*H*-indazol-5-yl]-5-methyl-1*H*-pyrazol-1-yl}-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one,

1-{6-[(4*M*)-4-(3-Amino-5-chloro-6-methyl-1*H*-indazol-4-yl)-5-methyl-3-phenyl-1*H*-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one,

or a pharmaceutically acceptable salt thereof.

~~45~~16. A ~~crystalline form of a~~ compound ~~according to any one of~~with the ~~preceding claims.~~following structure:

~~46~~



, or a pharmaceutically acceptable salt thereof.


17. A compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof, for use as a medicament.

18. ~~47. A~~ Use of a compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or

a pharmaceutically acceptable salt of an atropisomer thereof~~,~~ in the manufacture of a medicament for ~~use in treating~~the treatment of a cancer or a solid tumor.

~~48~~19. A pharmaceutical composition comprising a compound according to any one of the preceding claims, or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a crystalline form thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof, and at least one pharmaceutically acceptable excipient.


~~49. A compound of formula (2a),~~



, ~~(2a)~~

~~wherein A, B and C are as defined in any one of the preceding claims and R^{25} is hydrogen or a nitrogen-protecting group, or a salt thereof.~~


~~50. A compound of formula (2b*),~~



~~(2b*)~~

~~wherein A, C, R^{B2}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, R^{25} is hydrogen or a nitrogen-protecting group, wherein A is unsubstituted or substituted as defined in any one of the preceding claims, or a salt thereof.~~


~~51. A compound of formula (2c*),~~



(2c*).

wherein C, R^{A2}, R^{B2}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, R^{25} is hydrogen or a nitrogen-protecting group, wherein a is 0, 1, 2 or 3, or a pharmaceutically acceptable salt thereof.

52. A compound of formula (2d*),



(2d*),

wherein C, R^{ae}, R^{B2}, R^{N}, R^{B3} and R^{B4} are as defined in any one of the preceding claims, R^{25} is hydrogen or a nitrogen-protecting group, wherein the ---- lines indicate a single bond or a double bond, or a salt thereof.